Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Gossamer Bio (GOSS) EBT Margin (2022 - 2025)

Gossamer Bio's EBT Margin history spans 4 years, with the latest figure at 342.97% for Q4 2025.

  • For Q4 2025, EBT Margin rose 3489.0% year-over-year to 342.97%; the TTM value through Dec 2025 reached 357.08%, down 30612.0%, while the annual FY2025 figure was 351.67%, 30317.0% down from the prior year.
  • EBT Margin reached 342.97% in Q4 2025 per GOSS's latest filing, up from 362.73% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 1698.73% in Q3 2022 to a low of 397.03% in Q1 2025.
  • Average EBT Margin over 4 years is 501.03%, with a median of 138.57% recorded in 2024.
  • The largest YoY upside for EBT Margin was 3489bps in 2025 against a maximum downside of -38912bps in 2025.
  • A 4-year view of EBT Margin shows it stood at 1655.19% in 2022, then dropped by -12bps to 1453.0% in 2023, then tumbled by -126bps to 377.85% in 2024, then grew by 9bps to 342.97% in 2025.
  • Per Business Quant, the three most recent readings for GOSS's EBT Margin are 342.97% (Q4 2025), 362.73% (Q3 2025), and 333.13% (Q2 2025).